<html><body><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human use    final concept <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2228">paper</a></span> q3b: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on impurities in drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> dated and endorsed by the steering committee on 10 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1813">march</a></span> 1994   problem <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span>/objectives since it is the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> which is actually <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/138">consumed</a></span> and since new impurities can arise in the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> due to degradation of the active ingredient or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> of the active ingredient with other components, it is considered essential to review the requirements on impurities . this is felt as a natural and logical extension of the drug substance requirements and is needed to ensure consistency of approaches. the objective would be to prepare a consolidated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on impurities in new drug substances and dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>. background/status quo the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, which represents a consensus view on impurities in drug substances has been released for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>.  impact an international <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> covering impurities in drug substances and dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> will meet a critical need for consistency in approach to meet <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> requirements in the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span>. time frame the initial draft is under review and will be discussed in detail at the october meeting of the ewg. a step 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> will be required by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1813">march</a></span> 1995 if step 4, and an announcement of a consolidated ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on impurities (drug substance and dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>) is to be achieved at ich 3, november 1995. expert group the same expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group that dealt with the drug substance <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> would be appropriate.   -1- </body><html>